Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2022 call → NOWe need to determine if management explains where the company's business is going by narrating what its counterparties are themselves doing and scaling. The question asks: does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company ALREADY SUPPLIES OR SERVES, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to check the transcript. The company is ReneSola, a solar developer and operator. They discuss their own projects, acquisitions, IPP strategy, etc. They talk about their own pipeline, their own projects in Poland, Hungary, U.S., China. They mention acquisitions like Branston and Emeren. They talk about their own plans to build 200 MW, sell 400 MW, etc. They talk about PPA prices, market conditions. They do not seem to narrate what counterparties are doing. They talk about their own projects, their own development. They mention "we have strong presence in the world's fastest growing solar markets" but that's broad. They talk about "growing clean energy demand" but not specific counterparties. They mention "we are in the process of monetizing certain China projects" but that's their own. They talk about "our project development business" and "we expect to monetize approximately 400 megawatt of our mid to late stage pipeline in 2023." That's their own pipeline. They talk about "we are aligning our China strategy" etc. They talk about "we have good visibility into 2023 and expect this assets to contribute..." referring to their own assets. They talk about "we are also aligning our China strategy to the rest of the world under one strategy of develop, own or sell." So it's all about their own actions. They do mention "we have already signed attractive multiyear PPA for Branston project" but that's a contract, not a counterparty's expansion. They talk about "we completed the acquisition of Emeren" which is a company they acquired, not a counterparty they supply. They talk about "we decided to withhold 110 megawatt of project sales" etc. So it's all about their own decisions. The question is about whether management narrates what counterparties are doing.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.